Celltrion, Inc.

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 02/12/2024			5-day change	1st Jan Change
184,600.00 ^KRW	-1.28%		+6.40%	-8.39%

11-27	Celltrion, Inc. - Analyst/Investor Day
11-22	Celltrion Launches KRW100 Billion Share Buyback	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Celltrion, Inc.

Celltrion, Inc. - Analyst/Investor Day	11-27
Celltrion Launches KRW100 Billion Share Buyback	11-22	MT
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 25, 2024.	11-20	CI
Celltrion, Inc.'s Equity Buyback announced on October 25, 2024, has closed with 537,924 shares, representing 0.26% for KRW 94,709.84 million.	11-18	CI
Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024	11-18	CI
Celltrion to Acquire iQone Healthcare Switzerland in European Expansion Push	11-15	MT
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-14	CI
Trump makes Wall Street shine and depresses Europe	11-11
South Korean Shares Slide as Investors Remain Wary of New US Economic Policies After Trump Win	11-11	MT
Celltrion's Net Attributable Income Plunges 61% in Q3, Sales Up 31%	11-11	MT
Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement	10-30	MT
Celltrion's Zymfentra Monotherapy Shows Comparable Efficacy to Combo Therapy in IBD Study	10-30	MT
Celltrion to Carry Out Share Buyback to Boost Value	10-28	MT
Celltrion, Inc. announces an Equity Buyback for 537,924 shares.	10-25	CI
Celltrion, Inc. authorizes a Buyback Plan.	10-24	CI
Celltrion Signs Migraine Drug Development Deal with TEVA Pharmaceuticals	10-22	MT
Celltrion Launches New Cell Line Platform for Biopharmaceutical Efficiency Boost	10-16	MT
Celltrion Presents IBD Drug Data at European Gastroenterology Conference	10-16	MT
Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease	10-15	CI
Celltrion Secures Five-Year Cancer Drug Supply Deal from Brazil	09-16	MT
Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	08-29	CI
European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	08-25	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on June 14, 2024.	08-25	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on June 14, 2024.	08-25	CI
Atlantic Coastal Acquisition Corp. II announced that it expects to receive $11.22467 million in funding from Abpro Bio International, Inc., Celltrion, Inc.	08-21	CI

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,391

Sector

Biotechnology & Medical Research

Calendar

06/04/2025 - Q4 2024 Earnings Release (Projected)

More about the company